Why pharmacy remains a compelling mid-market play

Stability continues to present pharmacy as a compelling, high-resilience investment opportunity, write Mike Hess and Dawn Perez-Slavinski of Bass, Berry & Sims.

ByGuest Writer

27 April 2026•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare Value Creation Commentary Guest Opinion

Harbinger’s Mark Cuban confident that baseball investments will withstand lockout threat; Bregal Milestone adds to flurry of cybersecurity deals

5 hours ago · 6 mins read

Blackstone aims to relieve defense supply chain chokepoints with Falcata; Archimed in first deal from MED IV with Organika Health Products

21 October 2026 · 5 mins read

Security companies in vogue as Inflexion’s Ranger adds D&G Security; Advent joins string of PE firms opening Abu Dhabi office

21 October 2026 · 4 mins read

Advent opens Abu Dhabi office with Mehdi Iraqi at the helm

21 October 2026 · 2 mins read

Morgan Stanley Capital Partners scoops up The Rapid Group; Brightstar bets on automated warehouse trends with Material Handling Group USA

20 October 2026 · 4 mins read

Astorg’s Oxoid Remel to carve out microbiology diagnostic division of fellow portco Solabia; Platinum to buy lighting tower company Trime

20 October 2026 · 4 mins read

KKR to sell Infinity to Ares for $2.9bn; Thoma Bravo, GTCR and Francisco among PE firms making SaaS take-privates in 2026

19 October 2026 · 4 mins read

Why pharmacy remains a compelling mid-market play

Related articles